Pharmacological treatments for acute respiratory distress syndrome

Current Opinion in Critical Care

Volumn 16, Issue 1, 2010, Pages 62-68

  Frank, Angela J ^a   Thompson, B Taylor ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute respiratory distress syndrome; Alveolar clotting; Corticosteroids; Neutrophil elastase inhibitor; Surfactant

Indexed keywords

ALMITRINE; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALFACTANT; CORTICOSTEROID; DROTRECOGIN; LEUKOCYTE ELASTASE INHIBITOR; LUSUPULTIDE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SALBUTAMOL; SIVELESTAT; SURFACTANT; TISSUE FACTOR PATHWAY INHIBITOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; VASODILATOR AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCEPTUAL FRAMEWORK; DRUG DOSE INCREASE; DRUG EFFICACY; FLUID THERAPY; HUMAN; LOW DRUG DOSE; LUNG DEAD SPACE; LUNG EDEMA; LUNG LAVAGE; LUNG VENTILATION; META ANALYSIS; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG INJURY; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 75149161667     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328334b151     Document Type: Review

References (85)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349.
2. Pugin J, Verghese G, Widmer M-C, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999; 27:304-312.
3. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Resp Crit Care Med 2001; 163:1376-1383.
4. Smedly LA, Tonnesen MG, Sandhaus RA, et al. Neutrophil-mediated injury to endothelial cells: enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 1986; 77:1233-1243.
5. Baird BR, Cheronis JC, Sandhaus RA, et al. O2 metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. J Appl Physiol 1986; 61:2224-2229.
6. Zeiher BG, Matsuoka S, Kawabata K, Repine JE. Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit Care Med 2002; 30 (Suppl):S281-S287.
7. Weiland JE, Davis WB, Holter JF, et al. Lung neutrophils in the adult respiratory distress syndrome: clinical and pathophysiological significance. Am Rev Resp Dis 1986; 133:218-225.
8. Petty T. Protease mechanisms in the pathogenesis of acute lung injury. Ann NY Acad Sci 1991; 624:267-277.
9. Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:113-122.
10. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactantassociated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160:1843-1850.
11. Gregory TJ, Longmore WJ, MoxleyMA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1967-1981.
12. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562-1566.
13. Tomashefski JF Jr, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983; 112:112-126.
14. Ware LB, Camerer E, Welty-Wolf K, et al. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291:L307-L311.
15. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000; 21:436-466.
16. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS. Chest 2007; 131:954-963.
17. Bernard G, Luce J, Sprung C, et al. High dose corticosteroids in patients with adult respiratory distress syndrome. N Engl J Med 1987; 317:1565-1570.
18. Weigelt J, Norcross J, Borman K, Snyder WH III. Early steroid therapy for respiratory failure. Arch Surg 1985; 120:536-540.
19. Bone RC, Fisher CJ Jr, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987; 92:1032-1036.
20. Luce J, Montgomery A, Marks J, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138:62-68.
21. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome: diagnosis and treatment. Arch Surg 1985; 120:530-535.
22. Biffl WL, Moore FA, Moore EE, et al. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg 1995; 170:591-596.
23. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990; 97:138-143.
24. Braude S, Haslam P, Hughes D, et al. Chronic adult respiratory distress syndrome: a role for corticosteroids? Crit Care Med 1992; 20:1187-1189.
25. Keel JB, Hauser M, Stocker R, et al. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 1998; 65:258-264.
26. Meduri GU, Belenchia JM, Estes RJ, et al. Fibroproliferative phase of ARDS: clinical findings and effects of corticosteroids. Chest 1991; 100:943-952.
27. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. J Am Med Assoc 1998; 280:159-165.
28. Steinberg K, Hudson L, Goodman R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684.
29. Agarwal R, Nath A, Aggarwal AN, Gupta D. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007; 12:585-590.
30. Meduri GU, Marik PE, Chrousos GP, et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34:61-69.
31. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: metaanalysis. Br Med J 2008; 336:1006-1009.
32. Tang BMP, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and metaanalysis. Crit Care Med 2009; 37:1594-1603.
33. Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33:1-6.
34. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome. J Am Med Assoc 1999; 282:54-61.
35. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293-300.
36. Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006; 34:2749-2757. (Pubitemid 44610939)
37. Forel JM, Roch A, Papazian L. Paralytics in critical care: not always that bad guy. Curr Opin Crit Care 2009; 15:59-66.
38. Papazian L, Forel JM, Gacouin A, et al. Systematic two-day muscle relaxants course in the early phase of severe acute respiratory distress syndrome. A multicenter randomized controlled trial. Intensive Care Med 2009; 35:S6.
39. Hashimoto S, Okayama Y, Shime N, et al. Neutrophil elastase activity in acute lung injury and respiratory distress syndrome. Respirology 2008; 13:581-584.
40. Okayama N, Kakihana Y, Setoguchi D, et al. Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome. J Anesth 2006; 20:6-10.
41. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004; 32:1695-1702.
42. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977; 296:476-480.
43. Snow RL, Davies P, Pontoppidan H, et al. Pulmonary vascular remodeling in adult respiratory distress syndrome. Am Rev Respir Dis 1982; 126:887-892.
44. Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002; 346:1281-1286.
45. Osman D,Monnet X, Castelain V, et al. Incidence and prognostic value of right ventricular failure in acute respiratory distress syndrome. Intensive Care Med 2009; 35:69-76.
46. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-a review. Crit Care Med 2006; 34:871-877.
47. Bastarache J, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62:608-616.
48. Wang L, Bastarache J, Wickersham N, et al. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007; 36:497-503.
49. Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 2009; 37:1874-1880.
50. Bastarache JA, Wang L, Wang Z, et al. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294:L874-881.
51. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089.
52. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
53. Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29:894-903.
54. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33:952-961.
55. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618-623.
56. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157:1483-1488.
57. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998; 26:15-23.
58. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. J Am Med Assoc 2004; 291:1603-1609.
59. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med 1999; 25:911-919.
60. Adhikari NKJ, Burns KEA, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and metaanalysis. Br Med J 2007; 334:779-786.
61. Reyes A, Roca J, Rodriguez-Roisin R, et al. Effect of almitrine on ventilationperfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137:1062-1067.
62. Gallart L, Lu Q, Puybasset L, et al. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158:1770-1777.
63. Papazian L, Roch A, Bregeon F, et al. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160:473-479.
64. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-1677.
65. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991-996.
66. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334:1417-1421.
67. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. J Am Med Assoc 2005; 293:470-476.
68. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884-892.
69. Taut FJH, Rippin G, Schenk P, et al. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008; 134:724-732.
70. McAuley DF, Frank JA, Fang X, Matthay MA. Clinical relevant concentrations of b2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate- dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 2004; 32:1470-1476.
71. Saroti C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of highaltitude pulmonary edema. N Engl J Med 2002; 346:1631-1636.
72. Perkins GD, McAuley DF, Thickett DR, Gao F. The b-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173:281-287.
73. Perkins GD, Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008; 63:215-220.
74. O'Kane CM, McKeown SW, PerkinsGD, et al. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009; 37:2242-2249.
75. Matthay MA, Brower R, Thompson BT, et al. Randomized, placebo-controlled trial of an aerosolized beta-2 adrenergic agonist (albuterol) for the treatment of acute lung injury. Am J Respir Crit Care Med 2009; 179:A2166.
76. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference onARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824. (Pubitemid 24082248)
77. Esteban A, Fernández-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med 2004; 141:440-445.
78. Calfee CS, Eisner MD, Ware LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007; 35:2243-2250.
79. Gattinoni L, Pelosi P, Suter PM, et al. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease: different syndromes? Am J Respir Crit Care Med 1998; 158:3-11.
80. Meduri GU, Tolley EA, Chinn A, et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158: 1432-1441.
81. Ware LB, Conner ER, Matthay MA. Von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29:2325-2331.
82. Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35:1821-1828.
83. Thille AW, Richard JCM, Maggiore SM, et al. Alveolar recruitment in pulmonary and extrapulmonary acute respiratory distress syndrome: comparison using pressure-volume curve or static compliance. Anesthesiology 2007; 106:212-217.
84. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089.
85. Briot R, Frank JA, Uchida T, et al. Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest 2009; 135:269-275.